A study has discovered that giving early breast cancer patients’ palbociclib alongside hormone treatment stopped tumor growth entirely.
Browsing: drug development
Potentially practice-changing data was presented at 2018 ASH Annual Meeting and Exposition (December 1–4, 2018; CA, USA), read our round-up to discover the key studies. Highlights include the CASSINI and MAIA trial data,
A report from the Institute of Cancer Research has found that cancer patients are waiting longer than ever for access to innovative drug treatments.
The KEYNOTE-040 trial has shown that a novel immunotherapy treatment can extend the lives of some patients with advanced head and neck cancer for up to 3 years or more.
A three-drug antiemetic regimen including GERSC, rather than palonosetron, may lead to a reduction in the number hydration events required by patients receiving emetogenic chemotherapy
Erickson and colleagues evaluated hydration requirements with emetogenic chemotherapy and investigated the effects of an antiemetic drug combination.
Thousands of lung cancer patients in England are now eligible for a Keytruda® combination life-extending treatment through the Cancer Drugs Fund.
A new oral drug designed to improve efficacy of radiotherapy has been shown to be effective and safe as an adjunctive treatment for hard-to-treat cancers.
NICE has recommended the use of Lenvima® for untreated, advanced, unresectable hepatocellular carcinoma in adults.
Plinabulin: a novel immuno-oncology agent for the treatment of chemotherapy-induced neutropenia and advanced NSCLC
Find out about Plinabulin, a novel immuno-oncology agent in late-stage clinical trials for the treatment of chemotherapy-induced neutropenia and advanced NSCLC.
Find out insider details of the KEYNOTE-048 study in this exclusive interview with first author of the study, Barbara Burtness.